September 01, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at three upcoming investor conferences in September as follows: To access a live webcast of the presentation, visit
September 01, 2026 04:00 ET | Source: Boehringer Ingelheim Ingelheim, Germany, and Bracknell, United Kingdom Boehringer Ingelheim launches SCOVELLA® (velagliflozin oral solution), the first therapy developed and licensed in Great Britain for the treatment of insulin dysregulation (ID) in horses and ponies.1 Affecting an estimated one in five horses, insulin dysregulation is recognized as the primary underlying
Simon Cowley joins Health-ISAC to strengthen the organization’s global presence and engagement across Australia, New Zealand, and the Asia-Pacific region August 31, 2026 21:00 ET | Source: Health-ISAC MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) — Health Information Sharing and Analysis Center (Health-ISAC) announces the hiring of Simon Cowley as the new Asia Pacific (APAC) Health Sector Security & Partnerships Manager, effective
August 31, 2026 16:07 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered
August 31, 2026 16:07 ET | Source: Kyowa Kirin, Inc. TOKYO and PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced a voluntary agreement with the U.S. government to improve access and lower the cost of medicines for American patients. As part of
August 31, 2026 04:00 ET | Source: Xyra, LLC LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. XYRA LLC, a private biopharmaceutical company committed to developing innovative therapies for cardiac rhythm disorders
August 28, 2026 06:17 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics, Inc. through a court-supervised sale process. The
August 27, 2026 09:03 ET | Source: Royal Philips August 27, 2026 The solution combines Philips’ high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imricor’s exclusive portfolio of systems and consumables for MR-guided cardiac interventions. Amsterdam, the Netherlands – August 27, 2026: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor
At Booth 2C01, the company will highlight how customized medical-grade compounds, precision tubing, value-added processing, and healthcare solutions help regional OEMs develop and scale high-performance healthcare products. August 27, 2026 06:39 ET | Source: TekniPlex Wayne, PA, Aug. 27, 2026 (GLOBE NEWSWIRE) — TekniPlex Healthcare, a global leader in advanced materials science and precision manufacturing solutions for
August 26, 2026 23:58 ET | Source: Junshi Biosciences SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTS BUSINESS HIGHLIGHTS During
August 26, 2026 09:03 ET | Source: Royal Philips August 26, 2026 Cambridge, MA, USA and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received an up to US$33.7 million award under the Advanced Research Projects Agency for Health (ARPA-H, an agency within the U.S. Department of
August 25, 2026 10:23 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, Aug. 25, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval
August 24, 2026 17:05 ET | Source: Royal Philips August 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note (EMTN) program. The Notes are the
August 21, 2026 09:28 ET | Source: Allwyn The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winning local charity Spieren voor Spieren at the FORMULA 1® HEINEKEN DUTCH GRAND PRIX 2026 in the Netherlands. The F1® Allwyn Global Community Award 2026 trophy presented to
August 20, 2026 08:00 ET | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York.
